Marinus Pharmaceuticals Inc. (MRNS) Trading Up 12.4%
Shares of Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) were up 12.4% during mid-day trading on Friday . The company traded as high as $2.23 and last traded at $2.00, with a volume of 3,708,331 shares traded. The stock had previously closed at $1.78.
A number of equities analysts recently commented on the company. Jefferies Group reiterated a “buy” rating and set a $2.50 price objective (down previously from $13.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 14th. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Marinus Pharmaceuticals in a research report on Tuesday, May 3rd. Zacks Investment Research upgraded Marinus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research report on Tuesday, July 5th. Stifel Nicolaus reiterated a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 28th. Finally, Goldman Sachs Group Inc. downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday, June 14th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $7.80.
The company’s 50 day moving average price is $2.69 and its 200-day moving average price is $4.76. The firm’s market cap is $39.02 million.
Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.04. Analysts expect that Marinus Pharmaceuticals Inc. will post ($1.47) EPS for the current fiscal year.
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.